Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159656 | 0.94 | TLR7 (0.49) | TLR7GAATLR8LMNAHTT | |
| SCHEMBL6053148 | 0.88 | TLR7 (0.43) | TLR7GAATLR8LMNAMAPT | |
| SCHEMBL6053167 | 0.87 | TLR7 (0.42) | TLR7GAATLR8LMNAMAPT | |
| SCHEMBL3173290 | 0.86 | TLR7 (0.59) | TLR7TLR8LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5617910 | 0.85 | PPARG (0.35) | TLR7GAATLR8TSHR | |
| SCHEMBL5618015 | 0.85 | TLR7 (0.55) | TLR7TLR8LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5618843 | 0.85 | TLR7 (0.41) | TLR7GAATLR8LMNAMAPT | |
| SCHEMBL5617119 | 0.84 | TLR7 (0.45) | TLR7GAATLR8LMNASMN1; SMN2 | |
| SCHEMBL5618682 | 0.84 | TLR7 (0.40) | TLR7GAATLR8LMNAMAPT | |
| SCHEMBL5618101 | 0.84 | TLR7 (0.48) | TLR7TLR8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778963-B2 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1686992-A2 | HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051324-A2 | HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | IFNG, IRF3, IDO1 | TLR7 81/4885GAA 3130/4885TLR8 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.